Joe Tippens and Fenbendazole

Joe Tippens and Fenbendazole: Examining the Evidence Behind a Cancer Remission

His reported recovery, concurrent trial treatment, and what historical clinical data can—and cannot—explain

Evidence reviewed: October 27, 2026

A remission can be real while its cause remains uncertain. Joe Tippens reports that his cancer disappeared after he added fenbendazole and supplements during clinical-trial treatment. His account cannot isolate the contribution of any one intervention. Assessing the story requires taking both his reported recovery and the limits of the evidence seriously.

What Tippens Reports

Tippens describes small cell lung cancer diagnosed in 2016, treated with chemotherapy and radiation. In January 2017, he reports widespread progression and a grave prognosis, followed by clinical-trial participation. During the same period, he added fenbendazole, vitamin E, CBD oil and curcumin. He reports a clear PET scan in May 2017 and sustained absence of detectable disease, including a five-year milestone in 2022. These details are his account, not independently reviewed medical records. [1]

His blog openly mentions the trial. It also states that he withheld his fenbendazole use from the trial team until September 2017 because he feared exclusion. He recounts doctors describing his response as exceptional and interprets those comments as evidence for his added regimen. The conversations have not been independently verified. [1]

That distinction matters: the issue is not whether his public account entirely omitted conventional care, but whether it adequately establishes why the improvement occurred.

Concurrent Treatment: What the Sources Document

Tippens reportedly received pembrolizumab (Keytruda), an anti-PD-1 immunotherapy, during the same period as fenbendazole. That identification comes from secondary reporting; his trial identity, treatment record and dosing history were not independently verified for this review. Published pembrolizumab results therefore provide relevant context, rather than confirmation of his personal treatment history or the cause of his remission. [2]

The 2024 review by Nguyen and colleagues, Oral Fenbendazole for Cancer Therapy in Humans and Animals, also describes Tippens's concurrent clinical-trial participation. However, on page 3725 it calls the treatment a novel anticancer drug without naming it. Its source for this account is a 2019 KOCO news report, listed as reference 3 on page 3733. This is a review repeating a reported history, not a publication of Tippens's clinical records. [11]

Although that review mentions pembrolizumab in its patient tables on pages 3731–3732, those entries concern other patients. They cannot be used to confirm Tippens's treatment. The review supports the narrower statement that he was reportedly receiving another anticancer treatment at the same time. [11]

The strongest comparison would involve patients with the same pathology, disease burden, previous treatment, functional status and actual trial regimen, without fenbendazole. A prognosis given before trial treatment is not that comparison. Nor can the contribution of a new treatment be inferred simply because an outcome exceeded an earlier prognosis.

What the Pembrolizumab Studies Actually Found

Chung and colleagues pooled 83 patients with recurrent or metastatic small cell lung cancer who had received at least two previous treatment lines in KEYNOTE-028 and KEYNOTE-158. Patients had ECOG performance status 0–1; KEYNOTE-028 required PD-L1-positive tumours, whereas KEYNOTE-158 did not. These are selected trial populations, not an exact match for Tippens. [3]

Historical outcomes in the pooled SCLC cohorts
OutcomeResultInterpretation
Objective response19.3% (16/83)Partial and complete responses combined.
Complete response2/83 (approximately 2.4%)Uncommon, but documented during pembrolizumab monotherapy.
Response lasting at least 18 months61% of respondersNot 61% of all treated patients.
Estimated overall survival at 24 months21%Survival does not necessarily mean remission.

The response figures come from the published pooled analysis; the survival estimate is reported in the investigators' conference abstract. The studies evaluated pembrolizumab monotherapy, not a fenbendazole combination. They document antitumour activity in a minority, but do not establish the cause of any particular patient's improvement. [3] [4]

More prior treatment does not automatically make these patients a more difficult comparison group in every respect. Trial eligibility selected relatively fit participants, and PD-L1 selection, tumour burden, the interval since earlier therapy and other factors can affect outcomes. It is therefore inappropriate to assume these statistics underestimate Tippens's chances.

What is reasonably inferred? Given the reported pembrolizumab treatment, immunotherapy is a credible competing explanation for the remission. The data show that a minority can respond deeply and durably. They do not establish that his reported five-year course was typical, provide a reliable probability of that exact outcome, or resolve the uncertainty about his treatment records.

An Important Qualification: The SCLC Indication Was Withdrawn

Pembrolizumab received accelerated US approval in 2019 for metastatic SCLC after platinum chemotherapy and at least one additional treatment line. FDA lists withdrawal of that specific indication on March 30, 2021. Merck reported that KEYNOTE-604, the confirmatory trial, improved progression-free survival but did not meet its prespecified statistical threshold for overall survival. [5] [6]

This does not erase the responses observed in earlier studies. It does mean that evidence of occasional durable responses must be distinguished from confirmation of a survival benefit sufficient to maintain that indication. The historical comparison here is not a recommendation to use pembrolizumab for SCLC.

Laboratory studies

Fenbendazole has shown activity in cancer cells and mouse xenografts, including effects involving microtubules and cellular metabolism. In another study, it did not inhibit EMT6 tumour growth in mice; cell-culture effects with docetaxel were additive rather than synergistic. These findings are model-dependent and do not validate a human dosing regimen or establish clinical benefit. [7] [8]

Fenbendazole must also be distinguished from related compounds such as mebendazole, oxfendazole and levamisole. Clinical experience with another anthelmintic does not establish fenbendazole's safety or effectiveness. The present case cannot bridge that evidence gap.

Safety

Fenbendazole is a veterinary medicine without US approval for human use. In a published case, a patient with non-small cell lung cancer receiving pembrolizumab developed liver injury after self-administering fenbendazole. Liver function improved after withdrawal, and pembrolizumab was subsequently resumed without recurrent liver dysfunction, supporting the authors' attribution to fenbendazole, although an interaction could not be excluded. This is a different lung cancer subtype from Tippens's reported diagnosis. [9]

Another report describes severe, biopsy-supported liver injury associated with fenbendazole self-administration. Case reports cannot establish the frequency of this complication, but they show why absence of proven benefit should not be confused with absence of potential harm. [10]

What Can Be Concluded From This Story?

Tippens describes an exceptional and lasting recovery during concurrent clinical-trial treatment, reportedly pembrolizumab, although the available review literature does not independently establish his trial drug. Published SCLC data suggests that an immunotherapy response is possible; however, given such an exceptional outcome, a fenbendazole or synergistic effect cannot be ruled out and warrants further investigation.

This article evaluates evidence and is not a treatment protocol. Patients should discuss all medicines and supplements with their oncology team; trial participants should disclose them to the study team.

References

  1. Joe Tippens: personal account (self-reported history)
  2. Science Feedback (2023): reporting on the fenbendazole claim and concurrent treatment
  3. Chung et al. (2020): pooled KEYNOTE-028 and KEYNOTE-158 SCLC analysis
  4. Chung et al. (2019): trial abstract with survival estimates
  5. FDA: withdrawn cancer accelerated approvals
  6. Merck (March 1, 2021): SCLC indication withdrawal and confirmatory-trial outcome
  7. Dogra et al. (2018): fenbendazole in cancer cells and mouse xenografts
  8. Duan et al. (2013): fenbendazole in the EMT6 tumour model
  9. Yamaguchi et al. (2021): liver injury during fenbendazole self-administration and pembrolizumab treatment
  10. Thakurdesai et al. (2024): severe liver injury associated with fenbendazole
  11. Nguyen et al. (2024). Oral Fenbendazole for Cancer Therapy in Humans and Animals. Anticancer Research 44:3725–3735. Review; Tippens narrative cites a news report and does not name his trial drug.

Method note: Personal history is attributed to Tippens. His original medical records, trial identity and response adjudication were not verified in this review. Identification of pembrolizumab rests on secondary reporting; the clinical comparison is conditional. Historical trial results are not personalized predictions.

No comments:

Post a Comment